EGFR and non-small cell lung carcinoma: Another logical step is the addition of agents targeting the vascular endothelial growth factor or the epithelial growth factor receptor (EGFR) to an established chemotherapy regimen which has increased the treatment efficacy, for example in colorectal, breast, pancreatic, and NSCLC.